CCL7抗体;CCL7 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12476(CCL7 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P12476(CCL7 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

CCL7 (C-C motif chemokine ligand 7), also known as monocyte chemoattractant protein-3 (MCP-3), is a small secreted protein belonging to the CC chemokine family. It plays a critical role in immune regulation by recruiting monocytes, lymphocytes, dendritic cells, and eosinophils to sites of inflammation or injury through interactions with receptors such as CCR1. CCR2. and CCR3. CCL7 is implicated in various pathological processes, including cancer progression, autoimmune diseases, and chronic inflammatory conditions, due to its ability to modulate immune cell infiltration and activation.

Antibodies targeting CCL7 are essential tools for studying its biological functions and therapeutic potential. These antibodies are commonly used in research applications like ELISA, Western blotting, immunohistochemistry, and flow cytometry to detect CCL7 expression levels or neutralize its activity in experimental models. In cancer, CCL7 antibodies help investigate tumor microenvironment interactions, particularly how CCL7 promotes metastasis by attracting immunosuppressive cells or facilitating angiogenesis. In autoimmune disorders, such as rheumatoid arthritis or multiple sclerosis, blocking CCL7 signaling may reduce pathogenic inflammation.

The development of CCL7-specific antibodies also holds therapeutic promise. Preclinical studies explore their use in inhibiting chemokine-driven immune dysregulation, potentially offering targeted treatments for diseases with overactive CCL7 pathways. However, challenges remain in optimizing specificity and minimizing off-target effects. Overall, CCL7 antibodies serve as vital reagents for both mechanistic research and the development of novel immunomodulatory therapies.